DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma
Executive Summary
The DREAMM-2 trial of the antibody-drug conjugate belantamab mafodotin in relapsed/refractory multiple myeloma patients has hit its primary endpoint, giving GSK a chance to file for approval before its BCMA rivals.
You may also be interested in...
J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
ASH First Look: CAR-T Therapies Against BCMA, CD19 And More
CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets.
ASH Preview: J&J And Legend’s CAR-T Takes Center Stage
While bluebird bio, Celgene and GSK prepare to file, it’s time to shine for another myeloma contender.